Journal of inherited metabolic disease

RNA Treatments for Inherited Metabolic Diseases

Updated

Abstract

RNA-based therapies may provide new treatment options for inherited metabolic disorders (IMDs).

  • Inherited metabolic disorders are caused by deficiencies in enzymes, transporters, or cofactors, leading to significant metabolic dysfunction.
  • RNA therapies, including antisense oligonucleotides, small interfering RNAs, and messenger RNA therapeutics, aim to modulate gene expression and restore deficient proteins.
  • Delivery methods for RNA therapies, such as lipid nanoparticle packaging and tissue-specific systems, are critical for their clinical application.
  • The development of n-of-1 therapies has advanced personalized medicine for rare diseases, allowing for rapid and individualized drug development.
  • Ongoing innovation in RNA therapy chemistries and delivery technologies is necessary to enhance their effectiveness in treating IMDs.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

J.B. is in receipt of funding from The Medical Research Council, Great Ormond Street Hospital Children's Charity, Moderna Inc., and The Citrin Foundation and has received support from iECURE and the Citrin Foundation to attend meetings and/or travel. S.G. is in receipt of funding from Moderna Inc. and Great Ormond Street Hospital Children's Charity. There is no conflicts of interest from the other authors.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free